Ticker League

Novo Nordisk (NVO) Free Cash Flow Bridge

Pinpoint what moved Novo Nordisk's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

FCF YoY

-58.27%

OCF YoY

-9.64%

Capex YoY

+53.93%

FCF Conversion Δ

-30.5 pp

Free cash flow bridge for Novo Nordisk (NVO) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: −43.33B DKK

FCF bridge breakdown for Novo Nordisk (NVO) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow74.36B DKK
  • Operating Cash Flow−12.65B DKK
  • Capital Expenditure−30.68B DKK
  • Free Cash Flow31.03B DKK
Identity check: drivers reconcile to ΔNI within 0.00 DKK
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology